A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

NCT01614756 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects and Atopic Dermatitis Subjects

Interventions

BIOLOGICAL: BMS-981164
BIOLOGICAL: Placebo matching with BMS-981164

Sponsor

Bristol-Myers Squibb